SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Thygesen Kristian) "

Sökning: WFRF:(Thygesen Kristian)

  • Resultat 1-10 av 35
  • [1]234Nästa
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  • Mair, J., et al. (författare)
  • How is cardiac troponin released from injured myocardium?
  • 2018
  • Ingår i: European Heart Journal-Acute Cardiovascular Care. - : SAGE PUBLICATIONS LTD. - 2048-8726. ; 7:6, s. 553-560
  • Tidskriftsartikel (refereegranskat)abstract
    • Cardiac troponin I and cardiac troponin T are nowadays the criterion biomarkers for the laboratory diagnosis of acute myocardial infarction due to their very high sensitivities and specificities for myocardial injury. However, still many aspects of their degradation, tissue release and elimination from the human circulation are incompletely understood. Myocardial injury may be caused by a variety of different mechanisms, for example, myocardial ischaemia, inflammatory and immunological processes, trauma, drugs and toxins, and myocardial necrosis is preceded by a substantial reversible prelethal phase. Recent experimental data in a pig model of myocardial ischaemia demonstrated cardiac troponin release into the circulation from apoptotic cardiomyocytes as an alternative explanation for clinical situations with increased cardiac troponin without any other evidence for myocardial necrosis. However, the comparably lower sensitivities of all currently available imaging modalities, including cardiac magnetic resonance imaging for the detection of particularly non-focal myocardial necrosis in patients, has to be considered for cardiac troponin test result interpretation in clinical settings without any other evidence for myocardial necrosis apart from increased cardiac troponin concentrations as well.
  •  
2.
  • Oldgren, Jonas, et al. (författare)
  • Myocardial damage, coagulation activity and the response to thrombin inhibition in unstable coronary artery disease.
  • 2004
  • Ingår i: Thrombosis and haemostasis. - 0340-6245. ; 91:2, s. 381-7
  • Tidskriftsartikel (refereegranskat)abstract
    • Unstable coronary artery disease is in most cases associated with plaque rupture, activation of the coagulation system and subsequent intracoronary thrombus formation which may cause myocardial cell damage. The aim of the present analysis was to assess the relation between troponin T, markers of coagulation activity, i.e. prothrombin fragment 1+2, thrombin-antithrombin complex, soluble fibrin and D-dimer, and ischemic events, i.e. death, myocardial (re-)infarction or refractory angina. 320 patients with unstable coronary artery disease were randomized to 72 hours infusion with inogatran, a low molecular weight direct thrombin inhibitor, or unfractionated heparin. Patients with elevated troponin levels had higher levels of prothrombin fragment 1+2, soluble fibrin and D-dimer before, during, and at 24 hours after cessation of anticoagulant treatment. These troponin-positive patients tended to have worse short-term clinical outcome, without relation to markers of coagulation activity. Troponin-negative patients with unchanged or early increased thrombin generation during treatment had a cluster of ischemic events within 24 hours after cessation of the study drug. The 30-day ischemic event rate was 19 % in troponin-negative patients with unchanged or early increased prothrombin fragment 1+2, and 5.7 % in patients with decreased prothrombin fragment 1+2, p=0.006, and similarly 15 % in troponin-negative patients with unchanged or early increased thrombin-antithrombin complex and 4.5 % in patients with decreased thrombin-antithrombin complex, p=0.02. In conclusion, in unstable coronary artery disease a troponin elevation indicates higher risk and higher coagulation activity. However, among the troponin negative patients, with a lower risk and lower coagulation activity, a part of the patients seem to be non-responders to treatment with a thrombin inhibitor expressed as unchanged or raised coagulation activity and a raised risk of ischemic events early after cessation of treatment.
  •  
3.
  •  
4.
  • Aradi, Daniel, et al. (författare)
  • Platelet function testing in acute cardiac care - is there a role for prediction or prevention of stent thrombosis and bleeding?
  • 2015
  • Ingår i: Thrombosis and Haemostasis. - 0340-6245. ; 113:2, s. 221-230
  • Tidskriftsartikel (refereegranskat)abstract
    • The role of platelet function testing in acute coronary syndrome patients undergoing percutaneous coronary intervention remains controversial despite the fact that high platelet reactivity is an independent predictor of stent thrombosis and emerging evidence suggests also a link between low platelet reactivity and bleeding. In this expert opinion paper, the Study Group on Biomarkers in Cardiology of the Acute Cardiovascular Care Association and the Working Group on Thrombosis of the European Society of Cardiology aim to provide an overview of current evidence in this area and recommendations for practicing clinicians.
  •  
5.
  • Bolin, Kristian, et al. (författare)
  • Characteristics of finasteride users in comparison with non-users: a Nordic nationwide study based on individual-level data from Denmark, Finland, and Sweden
  • 2020
  • Ingår i: Pharmacoepidemiology and Drug Safety. - 1053-8569 .- 1099-1557. ; 29:4, s. 453-460
  • Tidskriftsartikel (refereegranskat)abstract
    • Purpose: Published epidemiological studies on the association between finasterideuse and the risk of male breast cancer have been inconclusive due to methodologicallimitations including a few male breast cancer cases included. Determinants of malebreast cancer have been studied, but it remains unexplored whether these are alsorelated to finasteride use and thereby constitute potential confounders. This studyaimed to assess whether there are differences between finasteride users andnonusers with regard to numerous potential confounders.Methods: In total, 246 508 finasteride users (≥35 years) were identified in the pre-scription registries of Denmark (1995-2014), Finland (1997-2013), and Sweden(2005-2014). An equal number of nonusers were sampled. The directed acyclic graph(DAG) methodology was used to identify potential confounders for the associationbetween finasteride and male breast cancer. A logistic regression model comparedfinasteride users and nonusers with regard to potential confounders that were mea-surable in registries and population surveys.Results: Finasteride users had higher odds of testicular abnormalities (odds ratio[OR] 1.40; 95% confidence interval [CI] 1.36-1.44), obesity (1.31; 1.23-1.39), exoge-nous testosterone (1.61; 1.48-1.74), radiation exposure (1.22; 1.18-1.27), and diabe-tes (1.07; 1.04-1.10) and lower odds of occupational exposure in perfume industry orin high temperature environments (0.93; 0.87-0.99), living alone (0.89; 0.88-0.91), liv-ing in urban/suburban areas (0.97; 0.95-0.99), and physical inactivity (0.70;0.50-0.99) compared to nonusers.Conclusions: Systematic differences between finasteride users and nonusers werefound emphasizing the importance of confounder adjustment of associationsbetween finasteride and male breast cancer.
  •  
6.
  • Bueno, Hector, et al. (författare)
  • Report of the European Society of Cardiology Cardiovascular Round Table regulatory workshop update of the evaluation of new agents for the treatment of acute coronary syndrome : Executive summary
  • 2019
  • Ingår i: European heart journal. Acute cardiovascular care.. - : SAGE PUBLICATIONS LTD. - 2048-8726. ; 8:8, s. 745-754
  • Tidskriftsartikel (refereegranskat)abstract
    • Regulatory authorities interpret the results of randomized controlled trials according to published principles. The European Medicines Agency (EMA) is planning a revision of the 2000 and 2003 guidance documents on clinical investigation of new medicinal products for the treatment of acute coronary syndrome (ACS) to achieve consistency with current knowledge in the field. This manuscript summarizes the key output from a collaborative workshop, organized by the Cardiovascular Round Table and the European Affairs Committee of the European Society of Cardiology, involving clinicians, academic researchers, trialists, European and US regulators, and pharmaceutical industry researchers. Specific questions in four key areas were selected as priorities for changes in regulatory guidance: patient selection, endpoints, methodologic issues and issues related to the research for novel agents. Patients with ST-segment elevation myocardial infarction (STEMI) and non-STEMI (NSTEMI) should be studied separately for therapies aimed at the specific pathophysiology of either condition, particularly for treatment of the acute phase, but can be studied together for other treatments, especially long-term therapy. Unstable angina patients should be excluded from acute phase ACS trials. In general, cardiovascular death and reinfarction are recommended for primary efficacy endpoints; other endpoints may be considered if specifically relevant for the therapy under study. New agents or interventions should be tested against a background of evidence-based therapy with expanded follow-up for safety assessment. In conclusion, new guidance documents for randomized controlled trials in ACS should consider changes regarding patient and endpoint selection and definitions, and trial designs. Specific requirements for the evaluation of novel pharmacological therapies need further clarification.
  •  
7.
  • Giannitsis, Evangelos, et al. (författare)
  • How to use D-dimer in acute cardiovascular care
  • 2017
  • Ingår i: European heart journal. Acute cardiovascular care.. - 2048-8726. ; 6:1, s. 69-80
  • Tidskriftsartikel (refereegranskat)abstract
    • D-dimer testing is important to aid in the exclusion of venous thromboembolic events (VTEs), including deep venous thrombosis and pulmonary embolism, and it may be used to evaluate suspected aortic dissection. D-dimer is produced upon activation of the coagulation system with the generation and subsequent degradation of cross-linked fibrin by plasmin. Many different assays for D-dimer testing are currently used in routine care. However, these tests are neither standardized nor harmonized. Consequently, only clinically validated assays and assay specific decision limits should be used for routine testing. For the exclusion of pulmonary embolism/deep vein thrombosis, age-adjusted cut-offs are recommend. Clinicians must be aware of the validated use of their hospital's D-dimer assay to avoid inappropriate use of this biomarker in routine care.
  •  
8.
  • Hao, Xian, et al. (författare)
  • Direct measurement and modulation of single-molecule coordinative bonding forces in a transition metal complex
  • 2013
  • Ingår i: Nature Communications. - 2041-1723. ; 4
  • Tidskriftsartikel (refereegranskat)abstract
    • Coordination chemistry has been a consistently active branch of chemistry since Werner’s seminal theory of coordination compounds inaugurated in 1893, with the central focus on transition metal complexes. However, control and measurement of metal–ligand interactions at the single-molecule level remain a daunting challenge. Here we demonstrate an interdisciplinary and systematic approach that enables measurement and modulation of the coordinative bonding forces in a transition metal complex. Terpyridine is derived with a thiol linker, facilitating covalent attachment of this ligand on both gold substrate surfaces and gold-coated atomic force microscopy tips. The coordination and bond breaking between terpyridine and osmium are followed in situ by electrochemically controlled atomic force microscopy at the single-molecule level. The redox state of the central metal atom is found to have a significant impact on the metal–ligand interactions. The present approach represents a major advancement in unravelling the nature of metal–ligand interactions and could have broad implications in coordination chemistry.
  •  
9.
  •  
10.
  • Hjorth Larsen, Ask, et al. (författare)
  • The atomic simulation environment-a Python library for working with atoms
  • 2017
  • Ingår i: Journal of Physics. - : Institute of Physics Publishing (IOPP). - 0953-8984 .- 1361-648X. ; 29:27
  • Forskningsöversikt (refereegranskat)abstract
    • The atomic simulation environment (ASE) is a software package written in the Python programming language with the aim of setting up, steering, and analyzing atomistic simulations. In ASE, tasks are fully scripted in Python. The powerful syntax of Python combined with the NumPy array library make it possible to perform very complex simulation tasks. For example, a sequence of calculations may be performed with the use of a simple 'for-loop' construction. Calculations of energy, forces, stresses and other quantities are performed through interfaces to many external electronic structure codes or force fields using a uniform interface. On top of this calculator interface, ASE provides modules for performing many standard simulation tasks such as structure optimization, molecular dynamics, handling of constraints and performing nudged elastic band calculations.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 1-10 av 35
  • [1]234Nästa
Typ av publikation
tidskriftsartikel (30)
forskningsöversikt (3)
doktorsavhandling (2)
Typ av innehåll
refereegranskat (32)
övrigt vetenskapligt (3)
Författare/redaktör
Thygesen, Kristian (26)
Jaffe, Allan S. (17)
Huber, Kurt (13)
Giannitsis, Evangelo ... (12)
Mair, Johannes (12)
Lindahl, Bertil, 195 ... (11)
visa fler...
Mueller, Christian (11)
Plebani, Mario (11)
Alpert, Joseph S (8)
Lindahl, Bertil (6)
Tubaro, Marco (6)
Hasin, Yonathan (6)
Tendera, Michal (5)
Katus, Hugo A (5)
White, Harvey D. (5)
Bolin, Kristian (5)
Hamm, Christian W. (5)
Bax, Jeroen J (5)
Fox, Keith A (5)
Lopez Sendon, José-L ... (5)
Möckel, Martin (5)
Pukkala, E (4)
Filippatos, Gerasimo ... (4)
Armstrong, Paul W. (4)
Morais, Joao (4)
Moeckel, Martin (4)
Newby, L Kristin (4)
Simoons, Maarten L (4)
Clemmensen, Peter M. (4)
Wallentin, Lars C. (4)
Nieminen, Markku S. (4)
Parkhomenko, Alexand ... (4)
Antman, Elliott M (4)
Priori, Silvia G (4)
Apple, Fred S. (4)
Green, A. (3)
Iversen, P (3)
Venge, Per (3)
Ohman, E. Magnus (3)
Chaitman, Bernard R. (3)
Katus, Hugo (3)
Koenig, Wolfgang (3)
Bassand, Jean-Pierre (3)
Wijns, William (3)
Hamm, Christian (3)
Collinson, Paul (3)
Morrow, David A. (3)
Brasso, K (3)
Underwood, Richard (3)
Ravkilde, Jan (3)
visa färre...
Lärosäte
Uppsala universitet (25)
Göteborgs universitet (9)
Umeå universitet (2)
Malmö universitet (1)
Chalmers tekniska högskola (1)
Språk
Engelska (35)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (21)
Naturvetenskap (2)

År

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy